2022-05 – Q1 2022 Reporting


  • SER150 clinical study in Australia is still delayed after Covid19 lockdowns
  • Serodus received Australian governmental refund (RDTI) for the SER150 Cl-009 study activities.
  • The Group qualified for and received a “Patent Voucher” from the Ministry of Commerce in Denmark supporting the patent strategy of the subsidiary Phlogo ApS.

Go to the report: Serodus ASA QR 2022 – Q1